OCI-Ly10 In Vivo Anti-Tumor Efficacy Assay

This assay is to provide OCI-Ly10-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

OCI-Ly10

Human

human B-cell non-Hodgkin lymphoma cell line established from the bone marrow of a 44-year-old man with B-cell non-Hodgkin lymphoma (B-NHL; diffuse large cell), stage 4B at relapse in 1983

Lymphoma

Oncology

In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays